» Articles » PMID: 39132825

Preeclampsia in the Context of COVID-19: Mechanisms, Pathophysiology, and Clinical Outcomes

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to the global COVID-19 pandemic, significantly impacting the health of pregnant women. Obstetric populations, already vulnerable, face increased morbidity and mortality related to COVID-19, aggravated by preexisting comorbidities. Recent studies have shed light on the potential correlation between COVID-19 and preeclampsia (PE), a leading cause of maternal and perinatal morbidity worldwide, emphasizing the significance of exploring the relationship between these two conditions. Here, we review the pathophysiological similarities that PE shares with COVID-19, with a particular focus on severe COVID-19 cases and in PE-like syndrome cases related with SARS-CoV-2 infection. We highlight cellular and molecular mechanistic inter-connectivity between these two conditions, for example, regulation of renin-angiotensin system, tight junction and barrier integrity, and the complement system. Finally, we discuss how COVID-19 pandemic dynamics, including the emergence of variants and vaccination efforts, has shaped the clinical scenario and influenced the severity and management of both COVID-19 and PE. Continued research on the mechanisms of SARS-CoV-2 infection during pregnancy and the potential risk of developing PE from previous infections is warranted to delineate the complexities of COVID-19 and PE interactions and to improve clinical management of both conditions.

Citing Articles

Evaluating the safety and efficacy of nirmatrelvir-ritonavir therapy in pregnant women with COVID-19: a systematic review and meta-analysis.

Hassan O, Elbhairy A, Siam A, Abdelwahab T, Hamad A, Mahmoud O Eur J Clin Pharmacol. 2025; .

PMID: 39948217 DOI: 10.1007/s00228-025-03808-8.

References
1.
Edlow A, Castro V, Shook L, Kaimal A, Perlis R . Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for SARS-CoV-2 During Pregnancy. JAMA Netw Open. 2022; 5(6):e2215787. PMC: 9185175. DOI: 10.1001/jamanetworkopen.2022.15787. View

2.
Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U . COVID-19, Pre-Eclampsia, and Complement System. Front Immunol. 2021; 12:775168. PMC: 8635918. DOI: 10.3389/fimmu.2021.775168. View

3.
Guida J, Cecatti J, Souza R, Pacagnella R, Ribeiro-Do-Valle C, Luz A . Preeclampsia among women with COVID-19 during pregnancy and its impact on maternal and perinatal outcomes: Results from a national multicenter study on COVID in Brazil, the REBRACO initiative. Pregnancy Hypertens. 2022; 28:168-173. PMC: 9085347. DOI: 10.1016/j.preghy.2022.05.005. View

4.
Lim M, Lakshminrusimha S, Hedriana H, Albertson T . Pregnancy and Severe ARDS with COVID-19: Epidemiology, Diagnosis, Outcomes and Treatment. Semin Fetal Neonatal Med. 2023; 28(1):101426. PMC: 9990893. DOI: 10.1016/j.siny.2023.101426. View

5.
Zhang J, Yang W, Roy S, Liu H, Roberts R, Wang L . Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission. Proc Natl Acad Sci U S A. 2023; 120(17):e2218623120. PMC: 10151465. DOI: 10.1073/pnas.2218623120. View